HEADER ANTIBIOTIC 28-DEC-00 1HHU TITLE BALHIMYCIN IN COMPLEX WITH D-ALA-D-ALA CAVEAT 1HHU MPD B 1016 HAS WRONG CHIRALITY AT ATOM C4 COMPND MOL_ID: 1; COMPND 2 MOLECULE: BALHIMYCIN; COMPND 3 CHAIN: A, B, C, D SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: AMYCOLATOPSIS SP.; SOURCE 3 ORGANISM_TAXID: 37632 KEYWDS ANTIBIOTIC, GLYCOPEPTIDE, CELL WALL PEPTIDES EXPDTA X-RAY DIFFRACTION AUTHOR C.LEHMANN,G.BUNKOCZI,G.M.SHELDRICK,L.VERTESSY REVDAT 11 29-JUL-20 1HHU 1 CAVEAT COMPND REMARK HETNAM REVDAT 11 2 1 LINK SITE ATOM REVDAT 10 24-JUL-19 1HHU 1 REMARK REVDAT 9 10-JUL-19 1HHU 1 REMARK REVDAT 8 24-APR-19 1HHU 1 REMARK SEQRES LINK REVDAT 7 06-FEB-13 1HHU 1 HETATM REVDAT 6 25-JUL-12 1HHU 1 REMARK HET HETNAM SITE REVDAT 6 2 1 HETATM ANISOU REVDAT 5 13-JUL-11 1HHU 1 VERSN REVDAT 4 18-AUG-09 1HHU 1 REMARK HET SITE LINK REVDAT 4 2 1 CRYST1 HETATM ANISOU TER REVDAT 4 3 1 CONECT MASTER REVDAT 3 14-APR-09 1HHU 1 HETATM ANISOU REVDAT 2 24-FEB-09 1HHU 1 VERSN REVDAT 1 05-SEP-03 1HHU 0 JRNL AUTH C.LEHMANN,G.BUNKOCZI,L.VERTESY,G.M.SHELDRICK JRNL TITL STRUCTURES OF GLYCOPEPTIDE ANTIBIOTICS WITH PEPTIDES THAT JRNL TITL 2 MODEL BACTERIAL CELL-WALL PRECURSORS JRNL REF J.MOL.BIOL. V. 318 723 2002 JRNL REFN ISSN 0022-2836 JRNL PMID 12054818 JRNL DOI 10.1016/S0022-2836(02)00146-8 REMARK 2 REMARK 2 RESOLUTION. 0.89 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 0.89 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 27.99 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.4 REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : SHELLS REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.084 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.084 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.100 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.200 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 4260 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 82360 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.082 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.082 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.099 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 5.200 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 4152 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 80430 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 320 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 210 REMARK 3 SOLVENT ATOMS : 125 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 630.50 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 354.50 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 28 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 6200 REMARK 3 NUMBER OF RESTRAINTS : 9467 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.027 REMARK 3 ANGLE DISTANCES (A) : 0.042 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.017 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.107 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.128 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : NULL REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.082 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.006 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.029 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.065 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: METHOD USED: MOEWS & KRETSINGER, REMARK 3 J.MOL.BIOL.91(1973)201-228 REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH AND HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: FRIDEL OPPOSITES DURING REFINEMENT NOT REMARK 3 MERGED REMARK 4 REMARK 4 1HHU COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 28-DEC-00. REMARK 100 THE DEPOSITION ID IS D_1290005732. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 15-SEP-98 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 7.00 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : EMBL/DESY, HAMBURG REMARK 200 BEAMLINE : X11 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9076 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 42306 REMARK 200 RESOLUTION RANGE HIGH (A) : 0.890 REMARK 200 RESOLUTION RANGE LOW (A) : 27.990 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.4 REMARK 200 DATA REDUNDANCY : 3.660 REMARK 200 R MERGE (I) : 0.01690 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 38.7600 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 0.89 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.00 REMARK 200 COMPLETENESS FOR SHELL (%) : 98.1 REMARK 200 DATA REDUNDANCY IN SHELL : 3.35 REMARK 200 R MERGE FOR SHELL (I) : 0.03390 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 24.67 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: DIRECT METHODS REMARK 200 SOFTWARE USED: SHELX REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 22.40 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.14 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 1M CIT, PH =7, 25% MPD, PH 7.00 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 13.99300 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1840 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 2470 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -10.4 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1700 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 2350 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -10.6 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: B, C REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 BALHIMYCIN IS A TRICYCLIC GLYCOPEPTIDE. THE SCAFFOLD IS REMARK 400 A HEPTAPEPTIDE WITH THE CONFIGURATION D-D-L-D-D-L-L. IT IS REMARK 400 FURTHER GLYCOSYLATED BY TWO MONOSACCHARIDES: A D-GLUCOSE REMARK 400 AND A 4-OXO-VANCOSAMINE. REMARK 400 HERE, BALHIMYCIN IS REPRESENTED GROUPING TOGETHER THE REMARK 400 SEQUENCE (SEQRES) AND TWO LIGANDS (HET) DVC AND BGC REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: BALHIMYCIN REMARK 400 CHAIN: A, B, C, D REMARK 400 COMPONENT_1: PEPTIDE LIKE SEQUENCE RESIDUES 1 TO 7 REMARK 400 COMPONENT_2: SUGAR RESIDUES 8 AND 9 REMARK 400 DESCRIPTION: BALHIMYCIN IS A TRICYCLIC HEPTAPEPTIDE REMARK 400 GLYCOSYLATED BY D-GLUCOSE (RESIDUE 8) ON REMARK 400 RESIDUE 4 AND BY 4-OXO-VANCOSAMINE REMARK 400 (RESIDUE 9) ON RESIDUE 6. REMARK 400 REMARK 400 THE BALHIMYCIN IS GLYCOPEPTIDE, A MEMBER OF ANTIBIOTIC, REMARK 400 ANTIMICROBIAL CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: BALHIMYCIN REMARK 400 CHAIN: A, B, C, D REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 COMPONENT_2: RESIDUE BGC REMARK 400 COMPONENT_3: RESIDUE DVC REMARK 400 DESCRIPTION: BALHIMYCIN IS A TRICYCLIC HEPTAPEPTIDE GLYCOSYLATED REMARK 400 BY D-GLUCOSE (RESIDUE 8) ON RESIDUE 4 AND BY 4-OXO- REMARK 400 VANCOSAMINE (RESIDUE 9) ON RESIDUE 6. REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A2002 DISTANCE = 6.13 ANGSTROMS REMARK 610 REMARK 610 MISSING HETEROATOM REMARK 610 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 610 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 610 I=INSERTION CODE): REMARK 610 M RES C SSEQI REMARK 610 MPD A 1019 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1GO6 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF BALHIMYCIN COMPLEXED WITH THE PEPTIDE LYS-DAL- REMARK 900 DAL REMARK 900 RELATED ID: 1HHY RELATED DB: PDB REMARK 900 CRYSTAL STRUCURE OF DEGLUCOBALHIMYCIN COMPLEXED WITH DAL-DAL REMARK 900 RELATED ID: 1HHZ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF DEGLUCOBALHIMYCIN COPMLEXED WITH CELL WALL REMARK 900 PENTAPEPTIDE DBREF 1HHU A 1 7 NOR NOR00709 NOR00709 1 7 DBREF 1HHU B 1 7 NOR NOR00709 NOR00709 1 7 DBREF 1HHU C 1 7 NOR NOR00709 NOR00709 1 7 DBREF 1HHU D 1 7 NOR NOR00709 NOR00709 1 7 SEQRES 1 A 7 MLU OMZ ASN GHP GHP OMY 3FG SEQRES 1 B 7 MLU OMZ ASN GHP GHP OMY 3FG SEQRES 1 C 7 MLU OMZ ASN GHP GHP OMY 3FG SEQRES 1 D 7 MLU OMZ ASN GHP GHP OMY 3FG MODRES 1HHU OMY A 6 TYR MODRES 1HHU OMY B 6 TYR MODRES 1HHU OMY C 6 TYR MODRES 1HHU OMY D 6 TYR HET MLU A 1 23 HET OMZ A 2 21 HET GHP A 4 15 HET GHP A 5 17 HET OMY A 6 20 HET 3FG A 7 19 HET MLU B 1 23 HET OMZ B 2 21 HET GHP B 4 15 HET GHP B 5 17 HET OMY B 6 20 HET 3FG B 7 19 HET MLU C 1 23 HET OMZ C 2 21 HET GHP C 4 15 HET GHP C 5 17 HET OMY C 6 20 HET 3FG C 7 19 HET MLU D 1 23 HET OMZ D 2 21 HET GHP D 4 15 HET GHP D 5 17 HET OMY D 6 20 HET 3FG D 7 19 HET BGC A 8 22 HET DVC A 9 23 HET DAL A 11 9 HET DAL A 12 11 HET CIT A1015 36 HET CIT A1016 36 HET CIT A1017 23 HET CIT A1018 35 HET MPD A1019 5 HET BGC B 8 22 HET DVC B 9 23 HET DAL B 11 9 HET DAL B 12 11 HET CIT B1015 18 HET MPD B1016 8 HET BGC C 8 22 HET DVC C 9 23 HET DAL C 11 9 HET DAL C 12 11 HET BGC D 8 22 HET DVC D 9 23 HET DAL D 11 9 HET DAL D 12 11 HETNAM MLU N-METHYL-D-LEUCINE HETNAM OMZ (BETAR)-3-CHLORO-BETA-HYDROXY-D-TYROSINE HETNAM GHP (2R)-AMINO(4-HYDROXYPHENYL)ETHANOIC ACID HETNAM OMY (BETAR)-3-CHLORO-BETA-HYDROXY-L-TYROSINE HETNAM 3FG (2S)-AMINO(3,5-DIHYDROXYPHENYL)ETHANOIC ACID HETNAM BGC BETA-D-GLUCOPYRANOSE HETNAM DVC (2R,4S,6S)-4-AZANYL-4,6-DIMETHYL-OXANE-2,5,5-TRIOL HETNAM DAL D-ALANINE HETNAM CIT CITRIC ACID HETNAM MPD (4S)-2-METHYL-2,4-PENTANEDIOL FORMUL 1 MLU 4(C7 H15 N O2) FORMUL 1 OMZ 4(C9 H10 CL N O4) FORMUL 1 GHP 8(C8 H9 N O3) FORMUL 1 OMY 4(C9 H10 CL N O4) FORMUL 1 3FG 4(C8 H9 N O4) FORMUL 5 BGC 4(C6 H12 O6) FORMUL 6 DVC 4(C7 H15 N O4) FORMUL 7 DAL 8(C3 H7 N O2) FORMUL 9 CIT 5(C6 H8 O7) FORMUL 13 MPD 2(C6 H14 O2) FORMUL 28 HOH *125(H2 O) LINK C MLU A 1 N OMZ A 2 1555 1555 1.33 LINK C OMZ A 2 N ASN A 3 1555 1555 1.33 LINK OH OMZ A 2 C3 GHP A 4 1555 1555 1.37 LINK C ASN A 3 N GHP A 4 1555 1555 1.36 LINK C GHP A 4 N GHP A 5 1555 1555 1.34 LINK C5 GHP A 4 OCZ OMY A 6 1555 1555 1.40 LINK O4 GHP A 4 C1 BGC A 8 1555 1555 1.42 LINK C GHP A 5 N OMY A 6 1555 1555 1.33 LINK C5 GHP A 5 CG1 3FG A 7 1555 1555 1.50 LINK C OMY A 6 N 3FG A 7 1555 1555 1.33 LINK ODE OMY A 6 C1 DVC A 9 1555 1555 1.42 LINK C DAL A 11 N DAL A 12 1555 1555 1.33 LINK C MLU B 1 N OMZ B 2 1555 1555 1.33 LINK C OMZ B 2 N ASN B 3 1555 1555 1.33 LINK OH OMZ B 2 C3 GHP B 4 1555 1555 1.39 LINK C ASN B 3 N GHP B 4 1555 1555 1.35 LINK C GHP B 4 N GHP B 5 1555 1555 1.33 LINK C5 GHP B 4 OCZ OMY B 6 1555 1555 1.39 LINK O4 GHP B 4 C1 BGC B 8 1555 1555 1.41 LINK C GHP B 5 N OMY B 6 1555 1555 1.32 LINK C5 GHP B 5 CG1 3FG B 7 1555 1555 1.50 LINK C OMY B 6 N 3FG B 7 1555 1555 1.33 LINK ODE OMY B 6 C1 DVC B 9 1555 1555 1.42 LINK C DAL B 11 N DAL B 12 1555 1555 1.31 LINK C MLU C 1 N OMZ C 2 1555 1555 1.35 LINK C OMZ C 2 N ASN C 3 1555 1555 1.34 LINK OH OMZ C 2 C3 GHP C 4 1555 1555 1.37 LINK C ASN C 3 N GHP C 4 1555 1555 1.34 LINK C GHP C 4 N GHP C 5 1555 1555 1.33 LINK C5 GHP C 4 OCZ OMY C 6 1555 1555 1.37 LINK O4 GHP C 4 C1 BGC C 8 1555 1555 1.42 LINK C GHP C 5 N OMY C 6 1555 1555 1.34 LINK C5 GHP C 5 CG1 3FG C 7 1555 1555 1.50 LINK C OMY C 6 N 3FG C 7 1555 1555 1.34 LINK ODE OMY C 6 C1 DVC C 9 1555 1555 1.42 LINK C DAL C 11 N DAL C 12 1555 1555 1.32 LINK C MLU D 1 N OMZ D 2 1555 1555 1.34 LINK C OMZ D 2 N ASN D 3 1555 1555 1.34 LINK OH OMZ D 2 C3 GHP D 4 1555 1555 1.39 LINK C ASN D 3 N GHP D 4 1555 1555 1.35 LINK C GHP D 4 N GHP D 5 1555 1555 1.34 LINK C5 GHP D 4 OCZ OMY D 6 1555 1555 1.38 LINK O4 GHP D 4 C1 BGC D 8 1555 1555 1.42 LINK C GHP D 5 N OMY D 6 1555 1555 1.34 LINK C5 GHP D 5 CG1 3FG D 7 1555 1555 1.49 LINK C OMY D 6 N 3FG D 7 1555 1555 1.35 LINK ODE OMY D 6 C1 DVC D 9 1555 1555 1.42 LINK C DAL D 11 N DAL D 12 1555 1555 1.32 CISPEP 1 GHP A 5 OMY A 6 0 -0.56 CISPEP 2 GHP B 5 OMY B 6 0 -2.07 CISPEP 3 GHP C 5 OMY C 6 0 2.22 CISPEP 4 GHP D 5 OMY D 6 0 0.79 CRYST1 22.705 27.986 44.490 90.00 93.18 90.00 P 1 21 1 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.044043 0.000000 0.002447 0.00000 SCALE2 0.000000 0.035732 0.000000 0.00000 SCALE3 0.000000 0.000000 0.022512 0.00000 MTRIX1 1 -0.963320 -0.049230 0.263810 12.62952 1 MTRIX2 1 -0.008840 0.988320 0.152140 -4.70875 1 MTRIX3 1 -0.268220 0.144230 -0.952500 64.23579 1 MTRIX1 2 0.994970 -0.004290 0.100070 -3.24436 1 MTRIX2 2 -0.004010 -0.999990 -0.002980 63.42650 1 MTRIX3 2 0.100080 0.002570 -0.994980 65.46110 1 MTRIX1 3 -0.984800 -0.037620 0.169560 15.83975 1 MTRIX2 3 0.011400 -0.988150 -0.153070 68.02299 1 MTRIX3 3 0.173310 -0.148820 0.973560 2.86101 1 MASTER 244 0 47 0 0 0 0 15 0 0 0 4 END